Gestational trophoblastic disease (GTD) is a proliferative disorder of trophoblastic cells. It defines a heterogeneous group of inter related lesions arising from the trophoblastic epithelium of the placenta.This study is based on retrospective analyses of the data of 34 adult patients with Gestational Trophoblastic Diseases who presented to NEMROCK in the period from 2006 to 2011. Follow up period extended till the end of December 2011, with analysis of response and survival.According to FIGO Prognostic Scoring for Gestational Trophoblastic Diseases, the majority of cases (73.5%) were low risk {score≤6}, and (26.5%) were high risk {score ≥7}. Although Gestational trophoblastic neoplasia is highly responsive to chemotherapy, resistance to first line chemotherapy was reported to occur in 56% of low risk cases and about 33% of high risk cases. Hysterectomy was done in 4 (11.7%) cases. In the current study; the five year disease free survival was 76.8%, while the overall survival was 90.2%.